Shots:
- Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS)
- As per the deal, Kaerus will receive a total of ~$450M incl. an upfront payment as well as development & commercial milestones
- KER-0193 is a BK channel modulator, which showed improvement across syndrome-relevant behavioral, sensory & cognitive deficits in preclinical models, with Servier planning to initiate P-II trial by 2026 for FXS in America & the EU
Ref: Servier| Image: Kaerus Bioscience | Press Release
Related News:- IDEAYA Biosciences Partners with Servier to Develop and Commercialize Darovasertib for Uveal Melanoma (UM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
